Ocrelizumab in the Treatment of Primary-Progressive Multiple Sclerosis

Medical Council
doi 10.21518/2079-701x-2018-1-77-78
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Remedium, Ltd.

Related search

Progressive Multiple Sclerosis: The Treatment Gap

Nature
Multidisciplinary
2012English

Differential Diagnosis of Primary Progressive Multiple Sclerosis

Clinical pharmacology and therapy
2018English

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle

Frontiers in Neurology
Neurology
2017English

Ocrelizumab for Relapsing or Primary Progressive MS

Prescriber
Pharmacology
2018English

Functional MR Imaging Correlates of Neuropsychological Impairment in Primary-Progressive Multiple Sclerosis

American Journal of Neuroradiology
MedicineNuclear MedicineNeurologyImagingRadiology
2010English

Loss of Circulating CD8+ CD161high T Cells in Primary Progressive Multiple Sclerosis

Frontiers in Immunology
AllergyImmunology
2019English

P.052 Late-Onset Adrenoleukodystrophy Mimicking Primary Progressive Multiple Sclerosis

Canadian Journal of Neurological Sciences
MedicineNeurology
2016English

Exercise Training in Progressive Multiple Sclerosis

International Journal of MS Care
NeurologySpecialized NursingAdvanced
2016English

Restoring Function in Progressive Multiple Sclerosis

The Lancet Neurology
Neurology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy